Vident Advisory, LLC Hutchmed (China) LTD Transaction History
Vident Advisory, LLC
- $10.5 Trillion
- Q3 2025
A detailed history of Vident Advisory, LLC transactions in Hutchmed (China) LTD stock. As of the latest transaction made, Vident Advisory, LLC holds 10,527 shares of HCM stock, worth $158,747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,527
Previous 11,374
7.45%
Holding current value
$158,747
Previous $171 Million
3.14%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding HCM
# of Institutions
57Shares Held
5.74MCall Options Held
0Put Options Held
0-
Schroder Investment Management Group London, X02.47MShares$37.2 Million0.03% of portfolio
-
Allianz Asset Management Gmb H Munich, 2M909KShares$13.7 Million0.02% of portfolio
-
Jane Street Group, LLC New York, NY340KShares$5.13 Million0.0% of portfolio
-
State Street Corp Boston, MA318KShares$4.79 Million0.0% of portfolio
-
Aia Group LTD Hong Kong, K3315KShares$4.76 Million0.1% of portfolio
About HUTCHMED (China) Ltd
- Ticker HCM
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 172,955,008
- Market Cap $2.61B
- Description
- HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...